ESMO Sarcoma & Rare Cancers congress
📅Save the date: March 12-14, 2026
📍Location: Lugano, Switzerland

SPAGN will once again be represented with a booth at the ESMO Sarcoma & Rare Cancers Congress, ensuring that the patient voice remains visible and engaged throughout the meeting.

We are also pleased to offer 15 complimentary registrations (free entry) for SPAGN members. To take advantage of this opportunity, please email us with the following details at info@sarcoma-patients.org:

Full Name 
Organisation's Name 
Full Address 
ESMO ID (member number), if known. 

Don't hesitate – Email us today & secure your spot! 

• Immunome announced positive topline results from the global Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors (December 15, 2025). Based on these results, Immunome plans to submit a New Drug Application to the U.S. FDA in Q2 2026. 
  
  Read company information here!📖

• Cogent announced that its submission for FDA approval of bezuclastinib in combination with sunitinib for second-line treatment of patients with advanced GIST has been accepted. The submission is based on Phase 3 data showing improved progression-free survival compared with sunitinib alone.
  
  Read company information here!📖

• Merck announced that pimicotinib for the treatment of tenosynovial giant cell tumor (TGCT) has been accepted for FDA review. The application is supported by clinical trial data demonstrating tumor responses in patients with TGCT.
  
  Read company information here!📖

February 2026

• Epithelioid Sarcoma Digital Expert Panel 2026 - February 2, 2026 - February 3, 2026 
• FORTRESS 2026- February 12, 2026 - February 14, 2026
• Histotripsy Demystified: Truths & Misconceptions Explained- February 25, 2026 

April 2026

• EMSOS meeting 2026- April 15, 2026 - April 17, 2026 
• AACR Annual Meeting 2026- April 17, 2026 - April 22, 2026

May 2026

• SPAGN Annual Conference 2026- May 1, 2026 - May 3, 2026
• ASCO 2026- May 29, 2026 - June 2, 2026